SCYNEXIS Inc
Company Profile
Business description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Contact
1 Evertrust Plaza
13th Floor
Jersey CityNJ07302 - 6548
USAT: +1 201 884-5485
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
29
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.30 | 22.50 | 0.26% |
| CAC 40 | 7,751.89 | 27.83 | -0.36% |
| DAX 40 | 23,997.48 | 64.25 | 0.27% |
| Dow JONES (US) | 42,270.07 | 54.34 | 0.13% |
| FTSE 100 | 8,772.38 | 55.93 | 0.64% |
| HKSE | 23,289.77 | 283.61 | -1.20% |
| NASDAQ | 19,113.77 | 62.10 | -0.32% |
| Nikkei 225 | 37,965.10 | 467.88 | -1.22% |
| NZX 50 Index | 12,418.89 | 137.58 | 1.12% |
| S&P 500 | 5,911.69 | 0.48 | -0.01% |
| S&P/ASX 200 | 8,434.70 | 24.90 | 0.30% |
| SSE Composite Index | 3,347.49 | 15.96 | -0.47% |